Literature DB >> 14559835

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Antonius E van Herwaarden1, Johan W Jonker, Els Wagenaar, Remco F Brinkhuis, Jan H M Schellens, Jos H Beijnen, Alfred H Schinkel.   

Abstract

The food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is the most abundant heterocyclic amine found in various protein containing foods. PhIP is mutagenic and carcinogenic in rodents, inducing lymphomas in mice and colon, mammary and prostate carcinomas in rats. It has also been implicated in human breast carcinogenesis. Humans on a normal Western diet are exposed to PhIP on a daily basis. The breast cancer resistance protein (BCRP/ABCG2) transports various anticancer drugs from cells, causing multidrug resistance. By its presence in the apical membrane of the intestine and bile canalicular membrane, it also protects the body from substrate drugs and toxins. We investigated whether Bcrp1 could affect PhIP exposure of the body because this could implicate BCRP activity in the cancer risk due to PhIP. Using polarized cell lines, we found that PhIP is efficiently transported by murine Bcrp1. In vivo pharmacokinetic studies showed that at a dose of 1 mg/kg [(14)C]PhIP the area under the curve for oral administration was 2.9-fold higher in Bcrp1(-/-) compared with wild-type mice (306 +/- 39 versus 107 +/- 15 h.ng/ml) and, for i.v. administration, 2.2 fold higher (386 +/- 36 versus 178 +/- 8.9 h.ng/ml). Wild-type mice cleared [(14)C]PhIP mainly by fecal excretion, but this shifted to primarily urinary excretion in Bcrp1(-/-) mice. In mice with a cannulated gall bladder, both hepatobiliary and direct intestinal excretion of [(14)C]PhIP were greatly impaired in Bcrp1(-/-) compared with wild-type mice (9.0 +/- 4.4 versus 36.5 +/- 9.4% and 1.5 +/- 0.8 versus 4.2 +/- 1.5%, respectively). We conclude that Bcrp1 effectively restricts the exposure of mice to ingested PhIP by decreasing its uptake from the gut lumen and by mediating hepatobiliary and intestinal elimination. Intra- or interindividual differences in BCRP activity in humans may thus also affect the exposure to PhIP and related food carcinogens, with possible implications for cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559835

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

Review 3.  Transporters in the intestine limiting drug and toxin absorption.

Authors:  R P J Oude Elferink; R de Waart
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

Review 4.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Efflux transporters: newly appreciated roles in protection against pollutants.

Authors:  David Epel; Till Luckenbach; Charlotte N Stevenson; Laura A Macmanus-Spencer; Amro Hamdoun; Tvrtko Smital
Journal:  Environ Sci Technol       Date:  2008-06-01       Impact factor: 9.028

Review 6.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.

Authors:  Kousei Ito; Hiroshi Suzuki; Toshiharu Horie; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 8.  ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

Authors:  Saroj Velamakanni; Shen L Wei; Tavan Janvilisri; Hendrik W van Veen
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

9.  Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Authors:  Serena Marchetti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Roberto Mazzanti; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2013-01-13       Impact factor: 3.850

10.  Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.

Authors:  H Chen; J Hao; L Wang; Y Li
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.